IGM Biosciences Inc

IGM Biosciences, Inc. is a clinical‑stage biotechnology company that designs and develops engineered IgM antibody therapeutics that exploit the multivalency and effector functions of the IgM scaffold to enhance target binding and immune-mediated tumor cell killing. The company’s pipeline includes multiple clinical programs, notably bispecific IgM candidates such as a CD20×CD3 program directed at B‑cell malignancies and an agonist targeting the death receptor DR5, and it advances these assets through clinical trials while seeking regulatory approvals or partner arrangements. Headquartered in Burlingame, California, IGM is publicly traded on Nasdaq and, as a development‑stage biotech, derives its value primarily from clinical progress, intellectual property and potential collaborations rather than product revenue.